Jasper Reports Wider Loss in Fiscal Q2
Jasper Therapeutics (NASDAQ:JSPR), a clinical-stage biotechnology company focused on therapies for mast cell-driven diseases like chronic urticaria, released its second quarter 2025 financial results on August 13, 2025. The most notable news was a net loss per share of $1.74 (GAAP) for Q2 2025. Jasper generated no revenue in the period. Cash and cash equivalents were $39.5 million as of Q2 2025. The quarter reflected both progress and setbacks, with rapid clinical advancements for its lead drug candidate, briquilimab, but also operational headwinds and continued losses.
Source: Analyst estimates for the quarter provided by FactSet.
Jasper Therapeutics is developing treatments for diseases driven by mast cells, a type of immune cell involved in allergic reactions and inflammatory diseases. Its main focus is briquilimab, a monoclonal antibody drug that targets the c-Kit pathway. This pathway is important for mast cell survival, so drugs that block it could reduce disease activity in conditions like chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU).
Source Fool.com
